1
|
Xu QY, Xie L, Zheng XQ, Liang XM, Jia ZJ, Liu YY, Liang XY, Liu LL, Yang TC, Lin LR. Anti-SARS-CoV-2 IgM Secondary Response Was Suppressed by Preexisting Immunity in Vaccinees: A Prospective, Longitudinal Cohort Study over 456 Days. Vaccines (Basel) 2023; 11:vaccines11010188. [PMID: 36680032 PMCID: PMC9862995 DOI: 10.3390/vaccines11010188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 01/10/2023] [Accepted: 01/13/2023] [Indexed: 01/17/2023] Open
Abstract
To obtain more insight into IgM in anti-SARS-CoV-2 immunity a prospective cohort study was carried out in 32 volunteers to longitudinally profile the kinetics of the anti-SARS-CoV-2 IgM response induced by administration of a three-dose inactivated SARS-CoV-2 vaccine regimen at 19 serial time points over 456 days. The first and second doses were considered primary immunization, while the third dose was considered secondary immunization. IgM antibodies showed a low secondary response that was different from the other three antibodies (neutralizing, total, and IgG antibodies). There were 31.25% (10/32) (95% CI, 14.30-48.20%) of participants who never achieved a positive IgM antibody conversion over 456 days after vaccination. The seropositivity rate of IgM antibodies was 68.75% (22/32) (95% CI, 51.80-85.70%) after primary immunization. Unexpectedly, after secondary immunization the seropositivity response rate was only 9.38% (3/32) (95% CI, 1.30-20.10%), which was much lower than that after primary immunization (p = 0.000). Spearman's correlation analysis indicated a poor correlation of IgM antibodies with the other three antibodies. IgM response in vaccinees was completely different from the response patterns of neutralizing, total, and IgG antibodies following both the primary immunization and the secondary immunization and was suppressed by pre-existing immunity induced by primary immunization.
Collapse
Affiliation(s)
- Qiu-Yan Xu
- Centre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
- Institute of Infectious Disease, School of Medicine, Xiamen University, Xiamen 361004, China
| | - Lin Xie
- Centre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
| | - Xin-Qi Zheng
- Centre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
| | - Xian-Ming Liang
- Centre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
| | - Zhi-Juan Jia
- Xiamen Boson Biotech Co., Ltd., Xiamen 361021, China
| | - Yan-Yun Liu
- Xiamen Boson Biotech Co., Ltd., Xiamen 361021, China
| | - Xiao-Yu Liang
- Xiamen Boson Biotech Co., Ltd., Xiamen 361021, China
| | - Li-Li Liu
- Centre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
- Institute of Infectious Disease, School of Medicine, Xiamen University, Xiamen 361004, China
| | - Tian-Ci Yang
- Centre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
- Institute of Infectious Disease, School of Medicine, Xiamen University, Xiamen 361004, China
- Correspondence: (T.-C.Y.); (L.-R.L.)
| | - Li-Rong Lin
- Centre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
- Institute of Infectious Disease, School of Medicine, Xiamen University, Xiamen 361004, China
- Correspondence: (T.-C.Y.); (L.-R.L.)
| |
Collapse
|
2
|
Kumari S, Saroj U, Verma A, Kumar A. Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi. J Family Med Prim Care 2022; 11:6385-6389. [PMID: 36618231 PMCID: PMC9810935 DOI: 10.4103/jfmpc.jfmpc_727_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 06/04/2022] [Accepted: 06/17/2022] [Indexed: 11/11/2022] Open
Abstract
Introduction Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as novel coronavirus (2019-nCoV). The disease presentation ranges from asymptomatic to severe acute respiratory failure requiring intensive care support. Anti-SARS-CoV-2 IgG antibodies are developed either by natural infection from SARS-CoV-2 or by vaccination against COVID-19. The persistence of IgG antibodies allows identification of the people who have been infected in the past, recovered from illness, and possibly become immune. 7 IgG detection and other serological assays will play an important role in research and surveillance. Aims and Objective The objective of the study is to assess anti-SARS-CoV-2 IgG titre among blood donors and to assess the decreasing incidence of COVID-19 in the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand. Materials and Methods An observational, cross-sectional study was conducted at the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand over a period of 2 months and 14 days from 06 February 2021 to 20 April 2021 who donated at least one unit of blood. Results This study recorded a greater number of male donors with B+ blood group. The anti-SARS-CoV-2 titre were mostly young adults between 18 and 31 years of age. Conclusion Seroprevalence was high in males having blood group B+ between 18 and 32 years of age.
Collapse
Affiliation(s)
- Sushma Kumari
- Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
| | - Usha Saroj
- Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
| | - Ashwini Verma
- Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India,Address for correspondence: Dr. Ashwini Verma, Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India. E-mail:
| | - Abhay Kumar
- Associate Professor, Department of Medicine, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
| |
Collapse
|
3
|
Xue JH, Wang YJ, Li W, Li QL, Xu QY, Niu JJ, Liu LL. Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody. Arch Pathol Lab Med 2022; 146:814-821. [PMID: 35380612 DOI: 10.5858/arpa.2022-0041-sa] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/30/2022] [Indexed: 12/24/2022]
Abstract
CONTEXT.— Neutralizing antibody detection can assess the incidence of COVID-19 and the effectiveness of vaccines. However, commercial reagents for neutralizing antibodies were developed after the anti-SARS-CoV-2 immunoglobulin (Ig) G and IgM antibodies. Therefore, some laboratories did not perform neutralizing antibody testing services because of multiple factors. OBJECTIVE.— To find a fast, accurate, and economic alternative for the detection of neutralizing antibodies for the development of COVID-19 screening programs. DESIGN.— The response and correlation of 3 antibodies (anti-spike protein neutralizing antibody, total anti-receptor-binding domain [RBD] antibody, and anti-RBD IgG) were determined by observing the dynamics in 61 participants for 160 days after vaccination. RESULTS.— The levels of neutralizing and anti-RBD IgG antibodies reached their peak values on day 42 after vaccination (120.75 IU/mL and 14.38 signal-to-cutoff ratio [S/CO], respectively). The total antibody levels peaked at 138.47 S/CO on day 35 after vaccination. The strongest correlation was found between neutralizing and anti-RBD IgG antibody levels (r = 0.894, P < .001). The area under the receiver operating characteristic curve for total antibody levels for the prediction of seropositivity for neutralizing antibodies was 0.881 (P < .001), and that for anti-RBD IgG antibody levels was 0.937 (P < .001). CONCLUSIONS.— Neutralizing and anti-RBD IgG antibody levels were strongly correlated, and thus anti-RBD IgG antibody levels can be used for the accurate assessment of immunity following SARS-CoV-2 infection or vaccination.
Collapse
Affiliation(s)
- Jian-Hang Xue
- From the Clinical Laboratory Center, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China (Xue, Wang, W. Li, Q.L. Li, Xu, Niu, Liu).,From the Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China (Xue)
| | - Yong-Jing Wang
- From the Clinical Laboratory Center, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China (Xue, Wang, W. Li, Q.L. Li, Xu, Niu, Liu)
| | - Wei Li
- From the Clinical Laboratory Center, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China (Xue, Wang, W. Li, Q.L. Li, Xu, Niu, Liu)
| | - Qiu-Ling Li
- From the Clinical Laboratory Center, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China (Xue, Wang, W. Li, Q.L. Li, Xu, Niu, Liu)
| | - Qiu-Yan Xu
- From the Clinical Laboratory Center, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China (Xue, Wang, W. Li, Q.L. Li, Xu, Niu, Liu)
| | - Jian-Jun Niu
- From the Clinical Laboratory Center, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China (Xue, Wang, W. Li, Q.L. Li, Xu, Niu, Liu)
| | - Li-Li Liu
- From the Clinical Laboratory Center, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China (Xue, Wang, W. Li, Q.L. Li, Xu, Niu, Liu).,From the Xiamen Clinical Laboratory Quality Control Center, Xiamen, China (Liu)
| |
Collapse
|
4
|
Bansal N, Raturi M, Bansal Y. Seroprevalence of SARS-CoV-2 among blood donors: A practical serosurveillance tool for COVID-19. Transfus Clin Biol 2021; 29:182-183. [PMID: 34961672 PMCID: PMC8673919 DOI: 10.1016/j.tracli.2021.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 11/10/2021] [Indexed: 11/19/2022]
Affiliation(s)
- N Bansal
- Department of Transfusion Medicine, VCSG Government Institute of Medical Science and Research, Srinagar, Uttarakhand, India.
| | - M Raturi
- Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Jolly Grant, Dehradun, Uttarakhand, India
| | - Y Bansal
- Department of Microbiology, VCSG Government Institute of Medical Science and Research, Srinagar, Uttarakhand, India
| |
Collapse
|